Skip to main content

Table 5 Factors associated with 28-day mortality in patients with proven IC

From: Systemic antifungal therapy for proven or suspected invasive candidiasis: the AmarCAND 2 study

Patients’ characteristics Survivors (N = 273) Non survivors (N = 130) P value
At ICU admission    
 Age 61.5 [51; 70.1] 66.5 [57.9; 78.8] <.01
 Male gender 171 (62.6) 83 (63.8) 0.81
 SAPSII 42 [30; 52] 56 [45; 67] <0.01
 SOFA score 8 [5; 10] 9.5 [7; 13] <0.01
 Immunosuppression 29 (10.6) 31 (23.8) <0.01
Reason for admission to ICU    <0.01
 Medical 88 (32.2) 66 (50.8)  
 Elective surgical 24 (8.8) 14 (10.8)  
 Emergency surgical 144 (52.7) 48 (36.9)  
 Trauma 17 (6.2) 2 (1.5)  
Red blood cell transfusion in ICU 141 (51.6) 79 (60.8) 0.09
Platelet transfusion in ICU 49 (17.9) 36 (27.7) 0.03
 At SAT initiation    
Body temperature (°C) 38 [37; 38.5] 37.6 [36.9; 38.2] <0.01
SOFA score 6 [3; 9] 9 [6; 13] <0.01
Septic shock 110 (40.3) 72 (55.4) <0.01
Severe sepsis 117 (42.9) 48 (36.9) 0.26
Invasive mechanical ventilation 191 (70) 97 (74.6) 0.33
Central venous catheter 261 (95.6) 126 (96.9) 0.53
Urinary catheterization 259 (94.9) 129 (99.2) 0.03
Hemodialysis or hemodiafiltration 68 (24.9) 53 (40.8) <0.01
Total parenteral nutrition 135 (49.5) 64 (49.2) 0.97
Corticosteroid treatment 44 (16.1) 38 (29.2) <0.01
Surgery just before or during ICU stay 209 (76.6) 75 (57.7) <0.01
Initial SAT    0.26
 Amphotericin B 4 (1.5) 2 (1.5)  
 Fluconazole 112 (41) 40 (30.8)  
 Voriconazole 2 (0.7) 1 (0.8)  
 Echinocandins 155 (56.8) 87 (66.9)  
SAT instituted before the knowledge of positive sample    0.14
 No 191 (70) 100 (76.9)  
 Yes 82 (30) 30 (23.1)  
  1. The results are given as n(%) or median (min; max), when indicated
  2. SAT systemic antifungal therapy, ICU intensive care unit, SOFA sequential organ failure assessment, SAPS II simplified acute physiology score